Category: CAS Medical Systems Inc.
A federal judge tosses 1 count of a patent infringement lawsuit filed by Covidien's Nellcor subsidiary against CAS Medical over patient monitoring technology.
A survey of CEOs and venture capital players reveals the gap between what CEOs want from their backers and what VCs think CEOs want.
A survey of 158 CEOs and 216 venture capital firms revealed a large gap between the chief executives' wish list for potential backers and what VCs think the CEOs want.
Startup CEOs in the IT and life science industries want VCs who are "entrepreneur friendly" and "collaborative" without being too hands-on in their approach, according to a survey sponsored by the National Venture Capital Assn.
Covidien's Nellcor patient monitoring subsidiary wants a judge to stop CAS Medical Systems from protesting the validity of a patent with the U.S. Patent & Trademark Office.
Shares of Accuray fall nearly 10% after the radiosurgery device maker lowers its sales forecast for the full year; plus, Q1 sales, earnings up for Henry Schein; LeMaitre Vascular's Q1 profits soar; Mindray's Q1 profits slide despite double-digit sales boost; Stereotaxis boosts Q1 sales, slashes losses; Steris profits spike in 2011; Symmetry Medical's Q1 bottom line plunges; Syneron boosts Q1 sales, losses widen; and more.
Accuray (NSDQ:ARAY) shares are down nearly 10% today as investors react to wider 3rd-quarter losses and a lower sales forecast for the rest of fiscal 2012.
The Sunnyvale, Calif.-based radiosurgery device maker reported losses of $14.9 million, or 21¢ per share, on sales of $101.8 million during the 3 months ended March 31.
Elekta's Q3 sales spike, earnings soar; Essilor's 2011 sales, earnings rise; DGT's sales rise, profits soar on divestiture; Q4, 2011 sales slump, losses widen for Stereotaxis; Sales, earning slide for Iridex in Q4; Losses soar for Imris in 2011; CasMed's sales slide, losses widen for Q4, 2011; and Oridion's 2011 sales rise, profits slide.
Elekta's Q3 sales spike, earnings soar
U-Systems wins a date with an FDA advisory panel to move forward on a pre-market application for the somo.v, the first ultrasound device to target breast cancer screening.
U-Systems won a date with the FDA to review its pre-market application for the first ultrasound device indicated for breast cancer screening.
The somo.v Abus device, which is set to undergo agency review on April 11, 2012, is already FDA-cleared for diagnostic use as an adjunct to a mammogram.
Accuray Inc.'s first-quarter results beat Wall Street's expectations, but investors still send its share price down 5 percent as the radiosurgery company's quarterly losses gape by more than 470 percent; also, results for CAS Medical Systems, Echo Therapeutics, CardioNet, Electromed, IntriCon, Bioject, Kips Bay Medical, Tornier, BioMimetic Therapeutics, Pro-Dex and Misonix.
Accuray (NSDQ:ARAY) shares are down today after the radiosurgery company reported surging first-quarter sales and beat Wall Street's earnings expectations, as investors reacted to net losses of nearly six times the Q1 2011 mark.
Accuray reported losses of $26.5 million, or 38 cents per share, on sales of $100.5 million for the three months ended Sept. 30. That's top-line growth of 163.9 percent compared with the same period last year, largely due to the massive infusion that followed ARAY's acquisition of rival TomoTherapy earlier this year.